On June 26, Moderna rose 5.23% in regular trading, trading at approximately $66.60/share, with turnover of $179 million. The rally was driven by multiple investment banks simultaneously raising their price targets on the stock, significantly boosting investor confidence.

Specifically, Piper Sandler raised its target price from $69 to $77 while maintaining an Overweight rating, and Jefferies raised its target from $45 to $53 while maintaining a Hold rating. According to FactSet, Moderna carries an average analyst rating of Hold with a mean price target of $48.25. The coordinated upgrades from multiple institutions sent a strong positive signal to the market.

The upgrades come amid a series of fundamental catalysts for Moderna. The company's mRNA seasonal influenza vaccine candidate mRNA-1010 recently received a unanimous 9-0 recommendation for approval from an FDA advisory committee, with a final regulatory decision expected by early August. Additionally, Moderna has completed organizational restructuring and appointed a new Chief Commercial Officer to prepare for the potential launch of up to three new vaccines over the coming years.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)